\-\ Texto\\:\\ \ \(0\)\
\-\ some\\ decreased\\ respiratory\\ effort\\ and\\ shortness\\ of\\ air\\.\\ \\ no\\ consolidation\\ appreciated\\.\ \(0\)\
\-\ esr\\-\\ 49\\ \\(0\\-20\\)\ \(0\)\
\-\ crp\\-\\ 9\\ \\(0\\-0\\.9\\)\ \(0\)\
\-\ blastomyces\\ dermatitidis\\ ag\\ 2\\.66\\ \\(2\\.1\\ \\â\\€\\“\\ 4\\ considered\\ positive\\)\ \(0\)\
\-\ treatment\\ usually\\ includes\\ amphotericin\\ b\\ or\\ one\\ of\\ the\\ azole\\ drugs\\,\\ which\\ is\\ normally\\ itraconazole\\.\\ \\ some\\ factors\\ influencing\\ treatment\\ include\\ 1\\)\\ the\\ clinical\\ form\\ and\\ severity\\ of\\ the\\ disease\\ and\\ 2\\)\\ the\\ immune\\ status\\ of\\ the\\ patient\\.\\ \\ if\\ the\\ infection\\ is\\ severe\\,\\ in\\ the\\ cns\\,\\ or\\ systemic\\,\\ a\\ lipid\\ formulation\\ of\\ amphotericin\\ b\\ is\\ preferred\\.\\ \\ if\\ the\\ disease\\ state\\ is\\ mild\\ or\\ moderate\\ and\\ excludes\\ the\\ cns\\,\\ then\\ itraconazole\\ is\\ the\\ drug\\ of\\ choice\\.\ \(0\)\
\-\ if\\ the\\ patient\\ is\\ immunocompetent\\ and\\ presents\\ with\\ an\\ acute\\ infection\\,\\ they\\ may\\ not\\ require\\ treatment\\ at\\ all\\.\\ \\ if\\ there\\ is\\ any\\ possibility\\ of\\ an\\ immunocompromised\\ state\\,\\ then\\ amphotericin\\ b\\ should\\ be\\ promptly\\ administered\\.\ \(0\)\
\-\ \\â\\€\\¢\\ chest\\ pa\\/lateral\\ \\-\\ normal\ \(0\)\
\-\ \\â\\€\\¢\\ ct\\ chest\\ w\\/o\\ contrast\\ \\-\\ \\ cavitary\\ left\\ lower\\ lobe\\ nodule\\ with\\ evidence\\ of\\ endobronchial\\ spread\\.\ \(0\)\
\-\ pulmonary\\ blastomycosis\ \(1\)\
\-\ acute\\ pulmonary\\ blastomycosis\\ may\\ be\\ initially\\ diagnosed\\ as\\ community\\-acquired\\ pneumonia\\.\\ \ \(0\)\
\-\ chronic\\ blastomycosis\\ is\\ often\\ misdiagnosed\\ as\\ tuberculosis\\ or\\ malignancy\\.\\ \ \(0\)\
\-\ sarcoidosis\\ and\\ primary\\ pulmonary\\ lymphoma\\ are\\ possibilities\\.\\ \\ \ \(0\)\
\-\ any\\ skin\\ lesions\\ may\\ be\\ mistaken\\ for\\ pyoderma\\ gangrenosum\\ or\\ keratoacanthoma\\.\ \(0\)\
\-\ 30\\ year\\ old\\ woman\\ presents\\ with\\ shortness\\ of\\ air\\ and\\ one\\ week\\ history\\ of\\ cough\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ blastomycosis\\:\\ 0\\.30705793665803\ \(0\)\
\-\ amphotericin\\:\\ 0\\.28778768240784197\ \(0\)\
\-\ itraconazole\\:\\ 0\\.20158867935757185\ \(0\)\
\-\ if\\:\\ 0\\.17540092626131862\ \(0\)\
\-\ the\\:\\ 0\\.16565007672962298\ \(0\)\
\-\ is\\:\\ 0\\.16534485675249502\ \(0\)\
\-\ state\\:\\ 0\\.1522867707655155\ \(0\)\
\-\ of\\:\\ 0\\.147692413167143\ \(0\)\
\-\ cns\\:\\ 0\\.1409565104600034\ \(0\)\
\-\ pulmonary\\:\\ 0\\.1380082332315428\ \(0\)\
\-\ or\\:\\ 0\\.13127420226882233\ \(0\)\
\-\ shortness\\:\\ 0\\.1210287384211293\ \(0\)\
\-\ blastomyces\\:\\ 0\\.12069374734068838\ \(0\)\
\-\ dermatitidis\\:\\ 0\\.12069374734068838\ \(0\)\
\-\ influencing\\:\\ 0\\.12069374734068838\ \(0\)\
\-\ pyoderma\\:\\ 0\\.12069374734068838\ \(0\)\
\-\ gangrenosum\\:\\ 0\\.12069374734068838\ \(0\)\
\-\ azole\\:\\ 0\\.11532931895674009\ \(0\)\
\-\ may\\:\\ 0\\.11393739456953715\ \(0\)\
\-\ formulation\\:\\ 0\\.11152319644668253\ \(0\)\
\-\ keratoacanthoma\\:\\ 0\\.11152319644668253\ \(0\)\
\-\ and\\:\\ 0\\.10916537292549915\ \(0\)\
\-\ misdiagnosed\\:\\ 0\\.10857093846830763\ \(0\)\
\-\ treatment\\:\\ 0\\.10785180038462683\ \(0\)\
\-\ then\\:\\ 0\\.10684835353113611\ \(0\)\
\-\ immunocompetent\\:\\ 0\\.10615876806273424\ \(0\)\
\-\ excludes\\:\\ 0\\.10235264555267667\ \(0\)\
\-\ air\\:\\ 0\\.09872899033356275\ \(0\)\
\-\ any\\:\\ 0\\.09755014877557545\ \(0\)\
\-\ some\\:\\ 0\\.09497059695486489\ \(0\)\
\-\ promptly\\:\\ 0\\.09494875615042128\ \(0\)\
\-\ ag\\:\\ 0\\.09403595919035346\ \(0\)\
\-\ immunocompromised\\:\\ 0\\.0931820946586708\ \(0\)\
\-\ endobronchial\\:\\ 0\\.09238001222165022\ \(0\)\
\-\ be\\:\\ 0\\.0918460848764473\ \(0\)\
\-\ possibilities\\:\\ 0\\.09162378878478006\ \(0\)\
\-\ infection\\:\\ 0\\.09117708882100019\ \(0\)\
\-\ effort\\:\\ 0\\.08896885361764198\ \(0\)\
\-\ lipid\\:\\ 0\\.087277578701921\ \(0\)\
\-\ mistaken\\:\\ 0\\.0867586765752748\ \(0\)\
\-\ one\\:\\ 0\\.08642079935450454\ \(0\)\
\-\ immune\\:\\ 0\\.08401154376466495\ \(0\)\
\-\ cavitary\\:\\ 0\\.08282594727804052\ \(0\)\
\-\ acute\\:\\ 0\\.08165330199506572\ \(0\)\
\-\ preferred\\:\\ 0\\.08010246113734844\ \(0\)\
\-\ chest\\:\\ 0\\.07967430058401744\ \(0\)\
\-\ administered\\:\\ 0\\.07810702780791513\ \(0\)\
\-\ drugs\\:\\ 0\\.07547616964159298\ \(0\)\
\-\ severity\\:\\ 0\\.07443387433968782\ \(0\)\
\-\ presents\\:\\ 0\\.07261040496261466\ \(0\)\
\-\ choice\\:\\ 0\\.07156204401505513\ \(0\)\
\-\ 49\\:\\ 0\\.07124322597846125\ \(0\)\
\-\ possibility\\:\\ 0\\.07018423627901355\ \(0\)\
\-\ consolidation\\:\\ 0\\.06975510758110104\ \(0\)\
\-\ normally\\:\\ 0\\.06880483096906469\ \(0\)\
\-\ drug\\:\\ 0\\.06867448204969019\ \(0\)\
\-\ appreciated\\:\\ 0\\.06804133213564222\ \(0\)\
\-\ spread\\:\\ 0\\.06779631942431476\ \(0\)\
\-\ systemic\\:\\ 0\\.06697283448875188\ \(0\)\
\-\ tuberculosis\\:\\ 0\\.06641451078860143\ \(0\)\
\-\ form\\:\\ 0\\.06598421893553437\ \(0\)\
\-\ require\\:\\ 0\\.06486835953963263\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.06392964619851181\ \(0\)\
\-\ factors\\:\\ 0\\.06383933657620586\ \(0\)\
\-\ disease\\:\\ 0\\.06335966320918605\ \(0\)\
\-\ as\\:\\ 0\\.06063835055654227\ \(0\)\
\-\ respiratory\\:\\ 0\\.0600332140661483\ \(0\)\
\-\ nodule\\:\\ 0\\.0595689450864965\ \(0\)\
\-\ pneumonia\\:\\ 0\\.0595689450864965\ \(0\)\
\-\ initially\\:\\ 0\\.05918356905556567\ \(0\)\
\-\ considered\\:\\ 0\\.058809101370961805\ \(0\)\
\-\ includes\\:\\ 0\\.05868659764112824\ \(0\)\
\-\ an\\:\\ 0\\.05771932592809755\ \(0\)\
\-\ moderate\\:\\ 0\\.056655849371438305\ \(0\)\
\-\ malignancy\\:\\ 0\\.05649989108264737\ \(0\)\
\-\ cough\\:\\ 0\\.056345749824976726\ \(0\)\
\-\ skin\\:\\ 0\\.056142982510599036\ \(0\)\
\-\ diagnosed\\:\\ 0\\.05466878568219999\ \(0\)\
\-\ they\\:\\ 0\\.05392506844561546\ \(0\)\
\-\ status\\:\\ 0\\.05266795332869789\ \(0\)\
\-\ 30\\:\\ 0\\.05148456760459794\ \(0\)\
\-\ week\\:\\ 0\\.05076179629249516\ \(0\)\
\-\ positive\\:\\ 0\\.04973117845132587\ \(0\)\
\-\ should\\:\\ 0\\.049244491547704876\ \(0\)\
\-\ often\\:\\ 0\\.049244491547704876\ \(0\)\
\-\ patient\\:\\ 0\\.04909352495428888\ \(0\)\
\-\ clinical\\:\\ 0\\.047829650263719575\ \(0\)\
\-\ severe\\:\\ 0\\.04777608618935289\ \(0\)\
\-\ usually\\:\\ 0\\.04751147120267806\ \(0\)\
\-\ decreased\\:\\ 0\\.04674797236925559\ \(0\)\
\-\ primary\\:\\ 0\\.04640621108568466\ \(0\)\
\-\ lymphoma\\:\\ 0\\.04494735136959001\ \(0\)\
\-\ all\\:\\ 0\\.04492578607011768\ \(0\)\
\-\ include\\:\\ 0\\.044904255864720195\ \(0\)\
\-\ chronic\\:\\ 0\\.04479712727699701\ \(0\)\
\-\ with\\:\\ 0\\.044334197804645155\ \(0\)\
\-\ lobe\\:\\ 0\\.04361396978167766\ \(0\)\
\-\ lesions\\:\\ 0\\.04334355990712735\ \(0\)\
\-\ evidence\\:\\ 0\\.04283716453710795\ \(0\)\
\-\ mild\\:\\ 0\\.04278207642852406\ \(0\)\
\-\ woman\\:\\ 0\\.039305279208676734\ \(0\)\
\-\ lower\\:\\ 0\\.038565504074800555\ \(0\)\
\-\ contrast\\:\\ 0\\.036669571349525205\ \(0\)\
\-\ which\\:\\ 0\\.03431718379579343\ \(0\)\
\-\ normal\\:\\ 0\\.030814096001412286\ \(0\)\
\-\ there\\:\\ 0\\.030029474710250758\ \(0\)\
\-\ not\\:\\ 0\\.02979395514947365\ \(0\)\
\-\ history\\:\\ 0\\.028834097142959144\ \(0\)\
\-\ ct\\:\\ 0\\.028732325038837696\ \(0\)\
\-\ are\\:\\ 0\\.028637619492734613\ \(0\)\
\-\ at\\:\\ 0\\.028506160415331605\ \(0\)\
\-\ left\\:\\ 0\\.02574463097343605\ \(0\)\
\-\ no\\:\\ 0\\.024542145374219553\ \(0\)\
\-\ year\\:\\ 0\\.023258519874319882\ \(0\)\
\-\ for\\:\\ 0\\.02287452703818188\ \(0\)\
\-\ old\\:\\ 0\\.022336230215803218\ \(0\)\
\-\ in\\:\\ 0\\.01877460918407537\ \(0\)\
